On August 19, Twist Bioscience Corp rose 12.21% in regular trading, trading at $135.01/share, with turnover of $47.75 million. The stock had closed down 6.68% the prior session at $116.10 before staging a sharp recovery.

The rally was driven by a broad biotech sector surge, with peer Moderna soaring approximately 88.5%, BioNTech climbing 16.36%, and Gilead Sciences gaining 2.36%, significantly lifting industry sentiment. On the fundamental side, the company reported fiscal Q3 revenue of $118.376 million on August 3, beating the consensus estimate of $114.49 million. More importantly, its Q4 revenue guidance of $123 million to $124 million substantially exceeded the FactSet estimate of $117.4 million. As a core DNA synthesis supplier within the AI-driven drug discovery value chain, the company has demonstrated accelerating protein business growth and recently completed a $300 million equity offering to expand production capacity, reinforcing improving fundamentals that supported the technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)